[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diuretics-drug-reactions\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diuretics-drug-reactions":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100434215","phase-1-mitigating-the-pro-inflammatory-phenotype-of-obesity-100434215",false,"NCT04934228","Mitigating the Pro-inflammatory Phenotype of Obesity","MAPLE","Inclusion Criteria:\n\n* Male or Female, age 18-79\n* Obese: BMI \\> 30 m\u002Fkg2\n* Hypertensive: blood pressure \\>130\u002F80\n* Elevated insulin resistance (HOMA-IR \\> 2.5)\n* Waist circ: \\>102 cm (men) and \\>88 cm (women)\n* Fasting glucose \\\u003C 126 mg\u002FdL\n* Fasting triglycerides \\\u003C 250 mg\u002FdL\n* HbA1c \\\u003C 6.5%\n* Willing to visit research lab (Fairway CTSU)\n* Willing to undergo a blood draw\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Current use of clonidine or beta-blockers\n* Current smoker or History of smoking in the past 3 months.\n* Hyperlipidemia: Fasting triglycerides \\> 250 mg\u002FdL\n* Currently taking hypertension medication\n* History of heart disease (e.g., myocardial infarction, stent, byass, heart attack, stroke, heart failure, valvular heart disease, cardiomyopathy)\n* History of neurological disorders\n* History of transplant\n* Actively participating in other studies, except for a registry study.","ALL","18 Years","79 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The purpose of this study is to examine the hypothesize that 4 weeks of sympathetic nerve activity (SNA) inhibition (oral clonidine) will cause a significant reduction in circulating blood concentrations and endothelial cell expression of inflammatory markers (e.g., TNF-α, IL-6).\n\nOur study is a prospective study using a randomized, double-blinded design to test 4 weeks of SNA blockade (oral clonidine) compared with a BP-lowering control condition (diuretic, hydrochlorothiazide) or a placebo.",[27,28,29,30,31,32],"Blood Pressure","Diabetes","Obesity","Insulin Resistance","Diuretics Drug Reactions","Sympathetic Nerve Activity","RECRUITING","2025-06-04",{"date":36,"type":37},"2025-06-05","ACTUAL",{"date":39,"type":37},"2021-07-01",{"date":41,"type":21},"2027-08-01",{"name":43,"class":44},"University of Kansas Medical Center","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":45},"100564572","phase-3-prevention-of-worsening-renal-function-of-intravenus-albumin-in-heart-failure-patients-100564572","NCT06630923","PREVENTION OF WORSENING RENAL FUNCTION OF INTRAVENUS ALBUMIN IN HEART FAILURE PATIENTS","HUMAN ALBUMIN IN HEART FAILURE - DIORASIS TRIAL","Inclusion Criteria:\n\n1. age over 18 yrs\n2. acute decompensation of CHF\n3. evidence of hepatic dysfunction by laboratory biochemical measurements or imaging (liver ultrasonography)\n4. history of CHF with previous use of an oral loop diuretic\n5. anticipated need for IV diuretic therapy for at least 72 hours\n\nThere is no pre-specified inclusion criterion with respect to ejection fraction\n\nExclusion Criteria:\n\n1. hemodynamic collapse (at least one of the following: systolic blood pressure (BP) \\\u003C 90 mmHg, or BP drop by \\>= 40 mmHg for \\>= 15 min, with end-organ hypoperfusion; need for inotropes (except of digoxin); need for cardiopulmonary resuscitation).\n2. hepatic dysfunction of other than cardiac etiology\n3. severe anemia (Hb\\\u003C8 g\u002FdL)\n4. uncontrolled hypertension or hypertensive emergency\u002Furgency\n5. pulmonary edema or pulmonary congestion necessitating use of IV vasodilators\n6. serum creatinine \\> 3 mg\u002FdL or glomerular filtration rate (GFR) \\\u003C 30 ml\u002Fmin","95 Years",{"count":55,"type":21},250,[57],"PHASE3","Patients hospitalized for acute decompensation of CHF are usually complicated by worsening renal function (WRF) which leads to diuretic resistance and inadequate decongestion as well as poor prognosis. WRF has been attributed to a reflex renal vasoconstriction elicited by intravascular volume depletion during brisk diuresis. The investigators hypothesize that CHF patients with hepatic dysfunction are more prone to WRF due to poor albumin production. This sub-group of CHF patients may benefit more (increased diuretic efficacy and protected against worsening renal function) by the use of IV loop diuretics in combination with an intravascular volume expander such as IV Human Albumin.",[31,60,61],"Heart Failure; With Decompensation","Albumin; Double",[63,64,65],"Human Albumin","Furosemide","Heart Failure","2024-10-04",{"date":68,"type":37},"2024-10-08",{"date":70,"type":37},"2023-01-14",{"date":72,"type":21},"2026-12-11",{"name":74,"class":44},"Democritus University of Thrace"]